Belite Bio Inc
NASDAQ:BLTE

Watchlist Manager
Belite Bio Inc Logo
Belite Bio Inc
NASDAQ:BLTE
Watchlist
Price: 159.27 USD -0.43% Market Closed
Market Cap: 5.6B USD

Relative Value

There is not enough data to reliably calculate the relative value of BLTE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BLTE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-56.1
Median 5Y
-101.3
Industry
21.4
Forward
-66.5
vs History
vs Industry
Median 3Y
-196.1
Median 5Y
-176
Industry
16.4
vs History
vs Industry
Median 3Y
-194.3
Median 5Y
-174.4
Industry
22.8
vs History
0
vs Industry
2
Median 3Y
14.8
Median 5Y
15.3
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-39.2
Median 5Y
-37.2
Industry
13
Forward
-62.5
vs History
vs Industry
Median 3Y
-50.5
Median 5Y
-90
Industry
16.5
Forward
-65
vs History
vs Industry
Median 3Y
-196.1
Median 5Y
-164.7
Industry
15.6
vs History
vs Industry
Median 3Y
-194.3
Median 5Y
-163.2
Industry
18.7
vs History
17
vs Industry
0
Median 3Y
14.8
Median 5Y
15.5
Industry
1.9

Multiples Across Competitors

BLTE Competitors Multiples
Belite Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Belite Bio Inc
NASDAQ:BLTE
5.1B USD 0 -104.7 -93.2 -93.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/S Multiple
Revenue Growth P/S to Growth
US
Belite Bio Inc
NASDAQ:BLTE
Average P/S: 71.8
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
17.2
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.4
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.2
3%
1.4
UK
AstraZeneca PLC
LSE:AZN
4.9
8%
0.6
CH
Novartis AG
SIX:NOVN
4.7
5%
0.9
US
Merck & Co Inc
NYSE:MRK
4.1
4%
1
DK
Novo Nordisk A/S
CSE:NOVO B
4.6
5%
0.9
IE
E
Endo International PLC
LSE:0Y5F
92.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
US
Belite Bio Inc
NASDAQ:BLTE
Average P/E: 24.3
Negative Multiple: -104.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Belite Bio Inc
NASDAQ:BLTE
Average EV/EBITDA: 439.8
Negative Multiple: -93.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Belite Bio Inc
NASDAQ:BLTE
Average EV/EBIT: 1 883.3
Negative Multiple: -93.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5